ID   HuH-6
AC   CVCL_4381
SY   HUH-6; HuH 6; HuH6; HUH6; Huh6
DR   BTO; BTO:0001670
DR   CLO; CLO_0050851
DR   ArrayExpress; E-MTAB-2770
DR   BioGRID_ORCS_Cell_line; 643
DR   BioSample; SAMN10987713
DR   cancercelllines; CVCL_4381
DR   CCRID; 1101HUM-PUMC000477
DR   CCRID; 3101HUMTCHu181
DR   Cell_Model_Passport; SIDM00062
DR   CLS; 305092
DR   Cosmic; 869168
DR   Cosmic; 869279
DR   Cosmic; 873714
DR   Cosmic; 1187329
DR   Cosmic; 1237546
DR   Cosmic; 1518228
DR   Cosmic; 1622750
DR   Cosmic; 2162537
DR   Cosmic; 2369478
DR   Cosmic; 2771602
DR   DepMap; ACH-000671
DR   GEO; GSM887148
DR   GEO; GSM888220
DR   GEO; GSM936762
DR   IARC_TP53; 28317
DR   LiGeA; CCLE_149
DR   Progenetix; CVCL_4381
DR   RCB; RCB1367
DR   Wikidata; Q54896848
RX   DOI=10.11418/jtca1981.12.3_221;
RX   DOI=10.11418/jtca1981.16.3_173;
RX   PubMed=57894;
RX   PubMed=8389256;
RX   PubMed=9359923;
RX   PubMed=9671767;
RX   PubMed=15767549;
RX   PubMed=20937217;
RX   PubMed=22460905;
RX   PubMed=23505090;
RX   PubMed=23887712;
RX   PubMed=30894373;
RX   PubMed=31063779;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=32899426;
WW   https://lccl.zucmanlab.com/hcc/cellLines/Huh6
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JFCR45 cancer cell line panel.
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (PubMed=9671767; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Asp (c.476C>A); ClinVar=VCV001026335; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239Asp (c.715A>G); ClinVar=VCV000234036; Zygosity=Heterozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.79%; Native American=0.3%; East Asian, North=80.92%; East Asian, South=17.99%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): CCRID; RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 8,12
ST   D16S539: 10,11
ST   D18S51: 13,21
ST   D19S433: 12,12.2
ST   D21S11: 29,30
ST   D2S1338: 18
ST   D3S1358: 14,17
ST   D5S818: 8,11
ST   D7S820: 11,12
ST   D8S1179: 10,11
ST   FGA: 19,24
ST   TH01: 7,8
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   1Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 35
//
RX   DOI=10.11418/jtca1981.12.3_221;
RA   Namba M., Nakabayashi H., Doi I., Sato J., Miyazaki M.;
RT   "Cellular characteristics and utilization of human hepatoma cell lines
RT   which were established in our laboratory and distributed by Japanese
RT   Cancer Research Resources Bank.";
RL   Tissue Cult. Res. Commun. 12:221-227(1993).
//
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
//
RX   PubMed=57894;
RA   Doi I.;
RT   "Establishment of a cell line and its clonal sublines from a patient
RT   with hepatoblastoma.";
RL   Gann 67:1-10(1976).
//
RX   PubMed=8389256; DOI=10.1093/carcin/14.5.987;
RA   Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T.,
RA   Harris C.C.;
RT   "p53 gene mutation and integrated hepatitis B viral DNA sequences in
RT   human liver cancer cell lines.";
RL   Carcinogenesis 14:987-992(1993).
//
RX   PubMed=9359923; DOI=10.18926/AMO/30789;
RA   Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y.,
RA   Fukaya K.-i., Ishioka C., Namba M.;
RT   "Yeast functional assay of the p53 gene status in human cell lines
RT   maintained in our laboratory.";
RL   Acta Med. Okayama 51:261-265(1997).
//
RX   PubMed=9671767; DOI=10.1073/pnas.95.15.8847;
RA   de la Coste A., Romagnolo B., Billuart P., Renard C.-A., Buendia M.-A.,
RA   Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., Perret C.;
RT   "Somatic mutations of the beta-catenin gene are frequent in mouse and
RT   human hepatocellular carcinomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:8847-8851(1998).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=20937217; DOI=10.1170/149;
RA   Di Masi A., Viganotti M., Antoccia A., Magrelli A., Salvatore M.,
RA   Azzalin G., Tosto F., Lorenzetti S., Maranghi F., Mantovani A.,
RA   Macino G., Tanzarella C., Taruscio D.;
RT   "Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell
RT   lines by WNT/beta-catenin pathway, microRNA expression and protein
RT   expression profile.";
RL   Cell. Mol. Biol. 56:OL1299-OL1317(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23505090; DOI=10.1002/hep.26402;
RA   Wang K., Lim H.Y., Shi S., Lee J., Deng S.-B., Xie T., Zhu Z.,
RA   Wang Y.-L., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K.,
RA   Xu J.-C.;
RT   "Genomic landscape of copy number aberrations enables the
RT   identification of oncogenic drivers in hepatocellular carcinoma.";
RL   Hepatology 58:706-717(2013).
//
RX   PubMed=23887712; DOI=10.1038/ncomms3218;
RA   Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P.,
RA   Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.;
RT   "High frequency of telomerase reverse-transcriptase promoter somatic
RT   mutations in hepatocellular carcinoma and preneoplastic lesions.";
RL   Nat. Commun. 4:2218.1-2218.7(2013).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001;
RA   Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S.,
RA   Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N.,
RA   Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P.,
RA   Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.;
RT   "Analysis of liver cancer cell lines identifies agents with likely
RT   efficacy against hepatocellular carcinoma and markers of response.";
RL   Gastroenterology 157:760-776(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32899426; DOI=10.3390/cancers12092510;
RA   Scherer D., Davila Lopez M., Goeppert B., Abrahamsson S.,
RA   Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D.,
RA   Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.;
RT   "RNA sequencing of hepatobiliary cancer cell lines: data and
RT   applications to mutational and transcriptomic profiling.";
RL   Cancers (Basel) 12:2510.1-2510.14(2020).
//